Patents by Inventor Andiappan Murugan
Andiappan Murugan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11524951Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.Type: GrantFiled: November 12, 2020Date of Patent: December 13, 2022Assignee: AstraZeneca ABInventors: Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn, Vasantha Krishna Kadambar, Chandrasekhara Reddy Chintakuntla, Andiappan Murugan, Claudio Edmundo Chuaqui
-
Publication number: 20210130318Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.Type: ApplicationFiled: November 12, 2020Publication date: May 6, 2021Inventors: Sam BUTTERWORTH, Maurice Raymond Verschoyle FINLAY, Richard Andrew WARD, Heather Marie REDFEARN, Vasantha Krishna KADAMBAR, Chandrasekhara Reddy CHINTAKUNTLA, Andiappan MURUGAN, Claudio Edmundo CHUAQUI
-
Publication number: 20210002275Abstract: The present application relates to a process for the preparation of crystalline form A of palbociclib having specific surface area more than 2 m2/g comprising one-pot process for the preparation of compound of formula (IV). The present application further relates to the preparation of acid-addition salts of palbociclib and their use for the synthesis of crystalline form A of palbociclib having specific surface area more than 2 m2/g.Type: ApplicationFiled: September 14, 2020Publication date: January 7, 2021Inventors: Andiappan MURUGAN, Vipinkumar Shriram KABRA, Chinna Saida Reddy GADE, Rama Rao GONDU, Shravankumar CHANDRASHEKAR, Krishnamoorthy PASUPATHY, Anandan KALAISELVAN
-
Patent number: 10858336Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.Type: GrantFiled: June 19, 2019Date of Patent: December 8, 2020Assignee: AstaZeneca ABInventors: Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn, Vasantha Krishna Kadambar, Chandrasekhara Reddy Chintakuntla, Andiappan Murugan, Claudio Edmundo Chuaqui
-
Patent number: 10807978Abstract: The present application relates to a process for the preparation of crystalline form A of palbociclib having specific surface area more than 2 m2/g comprising one-pot process for the preparation of compound of formula (IV). The present application further relates to the preparation of acid-addition salts of palbociclib and their use for the synthesis of crystalline form A of palbociclib having specific surface area more than 2 m2/g.Type: GrantFiled: July 3, 2017Date of Patent: October 20, 2020Assignee: DR. REDDY'S LABORATORIES LIMITEDInventors: Andiappan Murugan, Vipinkumar Shriram Kabra, Chinna Saida Reddy Gade, Rama Rao Gondu, Shravankumar Chandrashekar, Krishnamoorthy Pasupathy, Anandan Kalaiselvan
-
Publication number: 20190389834Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.Type: ApplicationFiled: June 19, 2019Publication date: December 26, 2019Applicant: AstraZeneca ABInventors: Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn, Vasantha Krishna KADAMBAR, Chandrasekhara Reddy CHINTAKUNTLA, Andiappan MURUGAN, Claudio Edmundo CHUAQUI
-
Publication number: 20190241561Abstract: The present application relates to a process for the preparation of crystalline form A of palbociclib having specific surface area more than 2 m2/g comprising one-pot process for the preparation of compound of formula (IV). The present application further relates to the preparation of acid-addition salts of palbociclib and their use for the synthesis of crystalline form A of palbociclib having specific surface area more than 2 m2/g.Type: ApplicationFiled: July 3, 2017Publication date: August 8, 2019Inventors: Andiappan MURUGAN, Vipinkumar Shriram KABRA, Chinna Saida Reddy GADE, Rama Rao GONDU, Shravankumar CHANDRASHEKAR, Krishnamoorthy PASUPATHY, Anandan KALAISELVAN
-
Publication number: 20190092746Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.Type: ApplicationFiled: May 29, 2018Publication date: March 28, 2019Applicant: AstraZeneca ABInventors: Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn, Vasantha Krishna KADAMBAR, Chandrashekar Reddy C MURUGAN, Andiappan MURUGAN
-
Publication number: 20160002261Abstract: Processes for the preparation of the compound of formula II and intermediate compounds for use in the processes.Type: ApplicationFiled: September 17, 2015Publication date: January 7, 2016Inventors: Neil Barnwell, Philip Cornwall, Duncan Michael Gill, Gareth P. Howell, Rebecca Elizabeth Meadows, Eric Merifield, Christopher William Mitchell, Andiappan Murugan, Philip O Keefe, Zakariya Mohamed Patel, James Barry Rose, John Singleton, Jane Withnall
-
Publication number: 20150119379Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.Type: ApplicationFiled: December 19, 2014Publication date: April 30, 2015Applicant: AstraZeneca ABInventors: Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn, Chandrasekhara Reddy Chintakuntla, Claudio Edmundo Chuaqui, Vasantha Krishna Kadambar, Andiappan Murugan
-
Publication number: 20140364601Abstract: Processes for the preparation of the compound of formula (II) and intermediate compounds for use in the processes.Type: ApplicationFiled: May 11, 2012Publication date: December 11, 2014Applicant: ASTRAZENECA ABInventors: Neil Barnwell, Philip Cornwall, Duncan Michael Gill, Gareth P. Howell, Rebecca Elizabeth Meadows, Andiappan Murugan, Philip O'Keefe, John Singleton, Jane Withnall, Eric Merifield, Christopher William Mitchell, Zakariya Mohamed Patel, James Barry Rose
-
Patent number: 8436024Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R6, R7, L, X and Y are as defined in the specification; together with processes and intermediates for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.Type: GrantFiled: October 1, 2010Date of Patent: May 7, 2013Assignee: Astrazeneca ABInventors: Andiappan Murugan, Lena Kristina Bergstrom, Anna Kristoffersson, Martin Lindsjö, Peter Olof Sjö, Mark David Ashton, Jon Meigh
-
Publication number: 20130053409Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.Type: ApplicationFiled: July 25, 2012Publication date: February 28, 2013Applicant: ASTRAZENECA ABInventors: Sam BUTTERWORTH, Maurice Raymond Verschoyle FINLAY, Richard Andrew WARD, Vasantha Krishna KADAMBAR, Chandrashekar Reddy C MURUGAN, Andiappan MURUGAN, Heather Marie REDFEARN
-
Publication number: 20110082155Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R6, R7, L, X and Y are as defined in the specification; together with processes and intermediates for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.Type: ApplicationFiled: October 1, 2010Publication date: April 7, 2011Applicant: AstraZeneca ABInventors: Andiappan Murugan, Lena Kristina Bergstrom, Anna Kristoffersson, Martin Lindsjö, Peter Olof Sjö, Mark David Ashton, Jon Meigh
-
Publication number: 20070259948Abstract: The present invention relates to compounds of formula (1), its solvates and pharmaceutically acceptable salts having antifungal activity and its pharmaceutical composition comprising an effective amount of compound of formula (1) wherein R is substituted alkyl, alkenyl, aryl, heteroaryl, 2-thienyl, 3-thienyl, halothienyl, haloalkyl, halophenyl, or pyrrolyl; and R1 and R2, each independent of the other, are hydrogen, halogen, or alkoxy. The invention also relates to a process for the preparation of said compounds by contacting the intermediate alcohol, prepared from 1,2-O-isopropylideneglyceraldehyde and substituted phenylacetates, with acid chlorides under appropriate conditions to obtain some of the preferred compounds of the invention.Type: ApplicationFiled: August 4, 2006Publication date: November 8, 2007Inventors: Mukund Keshav Gurjar, Radhika Dilip Wakharkar, Hanumant Bapurao Borate, Ramesh Ganesh Kelkar, Andiappan Murugan, Mohan Anand Chandavarkar, Shreerang Vidyadhar Joshi, Sharangi Ravindra Vaiude